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Tolerance, Skin Inflammation and Physicochemical Characteristics of WheatDerived Products Influence Cutaneous Sensitisation to Wheat Dr. Katrine L. Bogh, PhD, Ms. Anne-Sofie R. Ballegaard, Jeppe M Dr. Larsen, PhD, Mrs. Natalia Z. Maryniak, Dr. Charlotte B. Madsen; DVM, National Food Institute, Kgs. Lyngby, Denmark. INTRODUCTION: The safety of cosmetics containing hydrolysed wheat proteins has been questioned, due to reports of food allergy to wheat hydrolysates and breakage of oral tolerance to wheat after cosmetic usage. RATIONALE: Skin sensitising capacity of 5 commercial wheat products with different physicochemical characteristics were evaluated on skin with various barrier-defects and inflammatory conditions, in either wheat tolerant or na€ ıve rats. We hypothesised that several factors influence the skin sensitising capacity of wheat products. METHODS: Brown Norway rats bred on a wheat-free diet (na€ ıve rats), or a conventional chow (wheat-tolerant rats), were sensitised by skinapplication of unmodified wheat, enzyme hydrolysed or, one of three acid hydrolysed wheat products on either intact, slightly damaged, or skin with experimental irritant dermatitis or atopic dermatitis. Sensitising capacity of wheat products was evaluated by specific IgE and in vivo elicitation tests. RESULTS: Sensitising capacity of the 5 wheat products was dependent on the product's physicochemical characteristics, both in na€ ıve and tolerant rats. Whereas all 5 products could sensitise naive animals only the acid hydrolysed products could sensitise wheat-tolerant rats. Thus, acid hydrolysed wheat could break oral tolerance. The skin condition heavily influenced the sensitising capacity of the products, which was enhanced by skin damage and inflammation.
CONCLUSIONS: This study demonstrate that skin sensitisation can be driven by commercially available wheat-derived products, and is dependent on the specific physicochemical features of the product and the physical and inflammatory condition of the exposed skin. Addition of foodderived proteins to cosmetics should be carefully evaluated due to the risk of sensitisation. 
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METHODS:
In a double-blind, multi-centred, randomized parallel-group design (Clinicaltrials.gov, NCT02049294), we investigated whether omalizumab, in allergic asthmatics on high doses of inhaled/oral corticosteroid, could:(i) reduce sputum eosinophils, (ii) allow reduction in steroid doses without losing asthma control, and, (iii) modulate clonogenic activity of TSLP and IL-5 on eosinophil progenitor cells. RESULTS: From six academic centres, we recruited only 11 allergic asthmatics (elevated serum IgE, ACQ-5 > _1.5, sputum eosinophils >3% despite high-dose steroids). Recruitment was compromised due to two primary factors: (i) potentially eligible patients being prescribed Xolair Ò earlier, and without expected clinical response, and (ii) availability of anti-IL-5 biologics. Final analysis was powered only at 40% (drug: n 5 5, placebo: n 5 6; n 5 1 from each arm withdrawn earlier at physician's discretion). Omalizumab was unable to reduce sputum eosinophils after 32 weeks (P 5 0.6). Reduction of steroid dose caused 4/5 on placebo to exacerbate (80%) compared to 20% in the drug arm (P 5 0.2). No conclusive treatment effect was observed for blood eosinophils, fractional exhaled nitric oxide, ACQ-5 or FEV 1 (P>0.05). The enumerated eosinophil/basophil colony forming units were comparable in both arms, indicating that IgE blockade may not have a direct effect on the clonogenic potential of TSLP. CONCLUSIONS: It is unlikely that omalizumab is able to reduce sputum eosinophilia in allergic asthmatics maintained on high-dose corticosteroids. A larger clinical trial is necessary to confirm this.
